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Introduction
The optimal method of ventilating and oxygenating
patients with ALI or ARDS remains a hotly debated topic.
Recent advances in lung injury research have refocused
clinical attention on reduced tidal volumes and limited
peak airway pressures in order to diminish the impact of
gas delivery to lungs with abnormal compliance, volume,
and regional time constants [1]. Despite such focus, the
benefits of a pressure-limited or volume-limited strategy for
ALI remain controversial [2]. From the midst of multiple
ABC = arterial blood gas; ALI = acute lung injury; APRV = airway pressure release ventilation; ARDS = adult respiratory distress syndrome; BIS =
bispectral index; BSA = body surface area; CPAP = continuous positive airway pressure; FiO2, fractional inspired oxygen; ICU = intensive care unit;
IRV = inverse ratio ventilation; PAC = pulmonary artery catheter; PCV = pressure-controlled ventilation; PEEP = positive end-expiratory pressure;
SvO2 = mixed venous oxygen saturation.
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Abstract
Background The purpose of the present study is to determine whether airway pressure release
ventilation (APRV) can safely enhance hemodynamics in patients with acute lung injury (ALI) and/or
adult respiratory distress syndrome (ARDS), relative to pressure control ventilation (PCV).
Methods Patients with severe acute lung injury or ARDS who were managed with inverse-ratio
pressure control ventilation, neuromuscular blockade and a pulmonary artery catheter were switched to
APRV. Hemodynamic performance, as well as pressor and sedative needs, was assessed after
discontinuing neuromuscular blockade
Results Mean age was 58 ± 9 years (n = 12) and mean Lung Injury Score was 7.6 ± 2.1. Temperature
and arterial oxygen tension/fractional inspired oxygen (FiO2) were similar among the patients. Peak
airway pressures fell from 38 ± 3 for PCV to 25 ± 3 cmH2O for APRV, and mean pressures fell from
18 ± 3 for PCV to 12±2c m H 2O for APRV. Paralytic use and sedative use were significantly lower
with APRV than with PCV. Pressor use decreased substantially with ARPV. Lactate levels remained
normal, but decreased on APRV. Cardiac index rose from 3.2 ± 0.4 for PCV to 4.6 ± 0.3 l/min per m2
body surface area (BSA) for APRV, whereas oxygen delivery increased from 997 ± 108 for PCV to
1409 ± 146 ml/min for APRV, and central venous pressure declined from 18 ± 4 for PCV to
12 ± 4 cmH2O for APRV. Urine output increased from 0.83 ± 0.1 for PCV to 0.96 ± 0.12 ml/kg per
hour for APRV.
Conclusion APRV may be used safely in patients with ALI/ARDS, and decreases the need for
paralysis and sedation as compared with PCV-inverse ratio ventilation (IRV). APRV increases cardiac
performance, with decreased pressor use and decreased airway pressure, in patients with ALI/ARDS.
Keywords acute lung injury, adult respiratory distress syndrome, airway pressure release ventilation,
hemodynamics, neuromuscular blockade
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competing methods, the open lung model of ventilation
has surfaced as a method to titrate both tidal volume and
peak airway pressures, as well as positive end-expiratory
pressure (PEEP) to an individual’s lung mechanics [3].
Inherent in this model is an understanding of both the
dynamic and static pressure–volume curves – a frequently
problematic concept application. Moreover, it is difficult to
generate a static pressure–volume curve in clinical prac-
tice. Therefore, the active clinician remains at a loss for an
easily understandable and deployable system by which to
establish oxygenation, clear carbon dioxide, and optimally
monitor the patient’s response to the ventilatory strategy.
One alternative is APRV.
APRV is essentially a high-level continuous positive airway
pressure (CPAP) mode that is terminated for a very brief
period of time. It is this short release period that allows
carbon dioxide to be cleared. The lengthy time during
which the high-level CPAP is present results in substantial
recruitment of alveoli of markedly different regional time
constants, at rather low gas flow rates and lower airway
pressures. The establishment of intrinsic PEEP by the
short release time enhances oxygenation. Carbon dioxide
clearance is aided by recruitment of the patient’s lung at
close to total lung capacity; elastic recoil creates large
volume gas flow during the release period.
This mode is fundamentally different from cyclic ventila-
tion. It allows the patient to breathe spontaneously during
all of the phases of the cycle. Given the spontaneous
nature of the mode, it is hypothesized that there should be
no need for continuous infusions of neuromuscular block-
ing agents in patients placed on this mode of ventilation.
This may result in a shorter duration of intensive care unit
(ICU) stay and a reduced incidence of prolonged neuro-
muscular blockade syndrome. Furthermore, because
patients may be ventilated at lower airway pressures than
are required with cyclic ventilation, there may be a
reduced need for pressor support of hemodynamics to
ensure oxygen delivery.
The present exploratory study was conducted to investi-
gate these issues in a patient population with severe lung
injury who required inverse ratio PCV for oxygenation
failure. We found that APRV safely oxygenates and venti-
lates patients at lower airway pressures, virtually elimi-
nates the need for neuromuscular blockade, and reduces
the need for pressor support and sedation, while improv-
ing oxygen delivery in patients with ALI/ARDS.
Patients and methods
Patients in a mixed medical/surgical ICU of a tertiary care
university hospital with ALI/ARDS and an indwelling pul-
monary artery catheter (PAC) formed the subject group.
These study patients represent a convenience sample. All
of the patients were ventilated using IRV-PCV, with both
upper and lower inflection points eliminated from the
dynamic pressure–volume curve. Curve determination was
performed using a Pediatric–Adult Star 2000 Ventilator
(Infrasonics Inc, San Diego, CA, USA), with an integrated
waveform package. Setting changes were titrated to the
on-screen waveform appearance. Ventilator settings in
PCV achieved a partial carbon dioxide tension of
35–45 torr and a partial oxygen tension greater than
60 torr on an FiO2 of 0.60 or less. The patient ventilator
was then changed from the Adult Star ventilator to the
Evita 4 Pulmonary Workstation (Drager Medizintechnik
GmbH, Lubeck, Germany) with identical settings. All study
patients were maintained on continuous infusions of an
analgesic and a sedative. Some patients were also main-
tained on continuous infusions of a neuromuscular block-
ing agent. Daily assessment of the need for
pharmacologic relaxation was performed by protocol.
After allowing a 30-min period of equilibration, patients
were then switched to APRV mode. Initial high-level CPAP
settings were selected as 75% of the prior PCV-gener-
ated peak airway pressure. The initial duration at the high
CPAP (Thigh) was selected arbitrarily as 4.5 s. The initial
release time (Tlow) was arbitrarily set at 0.8 s. No lower
limit pressure during the release phase was set. The FiO2
was not altered. The Evita 4 ventilator parameters were
then titrated to the expiratory portion of the airway pres-
sure curve (Fig. 1), arterial blood gas (ABG) values for
carbon dioxide clearance, and the arterial oxygen satura-
tion to achieve comparable ventilation and oxygenation.
Neuromuscular blocking agents were discontinued and
assessed by a train of four stimulus at 50 mA on changing
to APRV. Patients who recovered a complete train of four
were no longer considered pharmacologically blocked.
Hemodynamic profiles, as well as ABG and lactate values,
were obtained immediately after changing to APRV.
Patients whose neuromuscular blocking agents were suc-
cessfully discontinued (ie recovery of a train of four) had
hemodynamic and laboratory values measured 30 min
after changing to APRV in order to assess the adequacy
of carbon dioxide clearance and perfusion. Patients who
remained pharmacologically blocked after 60 min of
having their blocking agent discontinued were excluded.
Sedative agents were titrated to a stimulated bispectral
index (BIS) value of 70 (range 65–75) on a pre-existing
protocol during neuromuscular blockade. Sedatives were
titrated to the BIS and patient comfort when neuromuscu-
lar blocking agents were discontinued. Patients were then
continued on APRV or returned to PCV, according to the
preferences of the treating physician.
Abstracted data common to all patients included age, diag-
nosis, chest radiograph interpretation, ventilator settings,
hemodynamic profiles, ABG, lactate, inotropic agents, neu-
romuscular blocking agents, sedatives, complicationsr
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during the transition from PCV to APRV, and urine output.
Data (means ± SD) were compared using a two-tailed Stu-
dent’s t-test (mean values) or c2 (percentage) as appropri-
ate. P < 0.05 was considered statistically significant.
One author (VF) was a respiratory therapist at the study
site before transition to the sponsoring ventilator
company. Following the transition that author had no
patient contact, but participated in data analysis.
Results
The results are summarized in Table 1. Mean age was
58 ± 9 years (n=12) and mean Lung Injury Score was
7.6 ± 2.1. Temperature (PCV 100.8 ± 1 versus APRV
100.6 ± 1°F; P > 0.5) and arterial oxygen tension/FiO2
ratio (PCV 168 ± 24 versus APRV 182 ± 18; P > 0.05)
were similar. Admitting diagnoses were pneumonia (22%),
intra-abdominal sepsis (45%), trauma (33%), bloodstream
infection (18%), and transfusion-related lung injury (1%).
With the change from PCV to APRV, peak airway pres-
sures fell from 38±3c m H 2O (PCV) to 25±3c m H 2O
(APRV; P < 0.01). Similarly, mean airway pressures fell
from 18±3c m H 2O (PCV) to 12±2c m H 2O (APRV;
P < 0.01). No patients sustained any untoward complica-
tions during the transition from PCV to APRV.
Neuromuscular blockade (vecuronium, cis-atracurium) use
(PCV 74% versus APRV 4%; P < 0.01) and use of seda-
tives (lorazepam, midazolam; PCV 100% versus APRV
68% of PCV dosage; P < 0.01) declined significantly with
APRV. The one patient who required continued neuromus-
cular blocking agents had sustained a severe traumatic
brain injury, and exhibited unmanageable intracranial pres-
sure values while off neuromuscular blocking agents.
Pressor (epinephrine, norepinephrine) use decreased sub-
stantially (PCV 92% versus APRV 45% of patients;
P < 0.01). Lactate levels remained normal, but declined
significantly on APRV (PCV 2.2 ± 0.4 mmol/l versus APRV
1.8 ± 0.3 mmol/l; P < 0.01). The mean cardiac index rose
from 3.2 ± 0.4 l/min per m2 BSA (PCV) to 4.6 ± 0.3 l/min
per m2 BSA (APRV; P < 0.01), whereas oxygen delivery
increased concomitantly from 997 ± 108 ml/min to
1409 ± 146 ml/min (PCV versus APRV; P < 0.01). In
association with these changes, the CVP declined from
18 ± 4 cmH2O (PCV) to 12±4c m H 2O (APRV;
P < 0.01). Mixed venous oxygen saturation (SvO2)
remained relatively constant between the two modes of
ventilation (P = 0.22). Urine output, however, increased
during the time period on APRV (0.96 ± 0.12 cc/kg per h;
P > 0.01) as compared with the immediately preceding
1 h (0.83 ± 0.1 cc/kg per h).
Discussion
This pilot study focuses on a select group of patients with
a severe lung injury and concomitant oxygenation failure.
Moreover, this small group of patients all had an indwelling
PAC for guidance of intravascular volume and/or pressor
support of oxygen delivery. All of the patients had normal
lactate levels and cardiac indices that exceeded 3 l/min
per m2 BSA. These values were taken as acceptable
markers of adequate perfusion and thorough resuscitation,
thus establishing a patient population that was believed to
be relatively stable. The causes of the severe lung injuries
Available online http://ccforum.com/content/5/4/221
Figure 1
Airway pressure and flow as a function of time using the Drager Evita 4
Pulmonary Workstation in APRV mode. Note that the upper tracing
indicates airway pressure, while the lower trace represents flow over
time. The airway pressure is held relatively constant, while the patient
is able to breathe spontaneously. The interruption in the airway
pressure trace marks the airway pressure release phase, and is short
relative to the time spent at the higher pressure. Reproduced with
permission from Drager, Inc.
Table 1
Data for selected parameters while patients were ventilated
with PCV-IRV or APRV
Parameter PCV-IRV APRV P
Pawpk (cmH2O) 38 ± 3 25 ± 3 <0.01
Pawmean (cmH2O) 18 ± 3 12 ± 2 <0.01
Paralytics (% of patients) 74 4 <0.01
Sedative use (% of PCV patients) 100 68 <0.01
Pressors (% of patients) 92 45 <0.01
Lactate (mmol/l) 2.2 ± 0.4 1.8 ± 0.3 <0.01
Cardiac index (l/min/m2) 3.2 ± 0.4 4.6 ± 0.3 <0.01
DO2 (ml/min) 997 ± 108 1409 ± 146 <0.01
SvO2 (%) 72 ± 4 80 ± 5 0.22
CVP (mmHg) 18 ± 4 12 ± 5 <0.01
Urine output (cc/kg per h) 0.83 ± 0.2 0.96 ± 0.3 <0.01
Values are means ± SD, or percentage, as indicated. Mean values
were compared by two-tailed t-test, whereas percentages were
evaluated using c2 tests. CVP, central venous delivery; DO2, oxygen
delivery; Pawmean, mean airway pressure; Pawpk, peak airway pressure.in the patients were diverse, as one may expect in a mixed
medical-surgical ICU, which attests to the protean nature
of the underlying disorders that may result in lung injury.
The primary questions that the present study addresses
are as follows: whether patients with a severe lung injury
requiring inverse ratio PCV may be safely transitioned to
APRV; whether APRV allows patients with a severe lung
injury on IRV-PCV and neuromuscular blockade to be
safely ventilated without neuromuscular blockade; whether
transitioning to APRV allows patients to be treated with
less sedation as compared with IRV-PCV; and whether
APRV improves hemodynamic performance in patients
with severe ALI/ARDS as compared with IRV-PCV.
An early trial in open-heart surgery patients [4] docu-
mented that patients on other forms of CPAP ventilation
may be safely switched to APRV. However, the result from
that study may not be directly applicable to patients with
severe lung injury. The present trial clearly demonstrates
that such transitioning is safe and well tolerated, even by
patients with inverse ratios approaching 4:1. Importantly,
such a transition is better tolerated by many patients than
was the original mode of mechanical ventilation with
regard to systemic oxygen delivery (Table 1). A more
recent trial [5] evaluated ARPV in patients with ARDS who
were sufficiently well to be supported entirely on pressure
support ventilation. This group and the one studied here
share similar findings, despite the differences in the
degree of lung injury when APRV was instituted. In both
studies, hemodynamics were improved by APRV. Impor-
tantly, we found that the beneficial effects of APRV were
related to the spontaneous breathing component as
demonstrated by improved alveolar recruitment.
Because APRV is a modified form of CPAP, spontaneous
breathing is an essential characteristic of the mode.
Otherwise, APRV becomes nothing more than PCV with
rather long inspiratory times and huge inspiratory : expira-
tory ratios. It is not uncommon to establish an ‘inspiratory :
expiratory ratio’ of 13:1 using APRV. The inspiratory : expi-
ratory ratio, however, is misleading during spontaneous
breathing on APRV. This is because the patient may
breathe throughout the entire phase time for each alterna-
tion of Thigh and Tlow at their respective pressures (Fig. 1).
Thus, neuromuscular blockade should be eliminated to
achieve the full potential benefits of APRV. These benefits
will principally include avoiding the muscular decondition-
ing that is associated with neuromuscular blockade, and
improving matching of recruitable lung volume with gas
volume. In this manner APRV does not result in overdisten-
sion, because the patient can simply exhale or inhale to
decrease or increase delivered gas volume to match the
available lung volume. We were able to virtually eliminate
neuromuscular blockade in this study after transitioning to
APRV. It is currently unclear whether treating all ALI/ARDS
patients with APRV will decrease duration of stay in ICU as
a result of eliminating or minimizing the use of neuromuscu-
lar blocking agents. A prospective randomized study is cer-
tainly warranted on this aspect of care, given the current
financial imperatives under which we practice.
Intuitively, APRV should be a more comfortable mode of
ventilation than any of the volume-limited or pressure-
limited modes, because APRV is simply a CPAP derivative
that allows spontaneous breathing. Therefore, one might
expect to be able to decrease the amount of sedative
agents used to achieve patient comfort and ‘synch’ with
the ventilator. Our data support this hypothesis. Sedative
use markedly decreased with the transition to APRV. The
reduced dosage of sedative that is required to maintain a
constant stimulated BIS value objectively support
increased comfort (or decreased discomfort) with the tran-
sition to APRV. This aspect of care may potentially be
characterized by the use of any of the numerous scales
available to quantify patient comfort, and should be incor-
porated into future investigations.
There were real benefits realized using APRV in this patient
population, namely improved oxygen delivery with reduced
pressor requirements. We titrated pressor infusions to
achieve a mean arterial pressure of 75 mmHg or greater,
warm extremities, and resolution of lactic acidosis (in com-
bination with volume loading for volume-recruitable cardiac
performance). Mean arterial pressure is an important para-
meter, because it is a physiologic end-point that the body
defends with vigor. It should be noted that pressors are not
used to treat hyperlactatemia that is not associated with
acidemia. Almost half of the patients were successfully
weaned off pressors when transitioned to APRV. The prob-
able explanation for the enhanced cardiac performance
with reduced pressor requirements stems from reduced
peak and mean airway pressures. The reduction in intratho-
racic pressure manifested as decreased central venous
pressure. It is likely that these related reductions resulted in
improved venous return and cardiac output.
Patients were not further volume loaded or transfused
packed red blood cells during the study period. Therefore,
the increase in cardiac performance cannot be readily
explained by volume-recruited cardiac performance or
changes in oxygen-carrying capacity. With enhanced
venous return, cardiac output increased as an expected
result of increased left ventricle end-diastolic volume.
Real-time trans-esophageal echocardiographic documen-
tation of an altered left ventricular chamber size may docu-
ment this process in the future. The improved
hemodynamic profile led to a 36% improvement in oxygen
delivery in this subgroup of patients relative to their oxygen
delivery while on PCV. The present study does not
address whether such a hyperdynamic state is beneficial.
However, it is clear that if such a state is appropriate for a
given individual, then APRV may represent a lower oxygen
Critical Care    August 2001 Vol 5 No 4 Kaplan et alcost method (relative to pressors) for enabling the body to
achieve that oxygen delivery.
One should note that the patients studied here had their
sedative infusions titrated to an objective criteria – the
BIS value. This value has been well correlated with
improvements in time to awakening from sedation in the
operating room, as well as with decreased recall phenom-
enon in the operating room and ICU. It is likely that the
sedative need decreased as patient comfort improved
during positive-pressure ventilation by transitioning to a
spontaneous breathing mode. It is also possible that the
increased cardiac performance resulted from increased
catecholamine tone as the patients awoke. However,
none of the patients were fully awake during the study
period; they simply required less sedative to achieve the
target BIS monitored level of sedation. Thus, the
increased cardiac performance is probably not an
expected commensal of awakening.
An earlier study in dogs with and without parenchymal
lung injury [6] compared APRV with conventional positive-
pressure ventilation, and assessed the hemodynamics.
Unsurprisingly, conventional ventilation resulted in
reduced blood pressure, stroke volume and cardiac per-
formance, including systemic oxygen delivery. The results
reported here closely support and buttress the animal
data, although the ventilator modes were introduced in
opposite orders. The lower airway pressures achieved
with APRV have recently been cited [7,8] as an essential
element in the care of neonates and pediatric patients with
ARDS or congenital cardiac anomalies, and as an adjunc-
tive support during extracorporeal membrane oxygenation
therapy. Despite the recognition of reduced airway pres-
sures (peak, plateau, mean), there has been relatively little
data on the hemodynamic impact of APRV. The present
study clearly documents the beneficial effects of APRV on
cardiac performance in patients with severe ALI/ARDS.
It is unsurprising that lactate levels remained normal,
because these were well-perfused patients whose mean
arterial pressures were held relatively constant. However, it
is important that the measured lactate declined with the
transition to APRV. Concomitantly, the increased cardiac
performance was also reflected in an increased urine
output as an indicator of improved end-organ perfusion.
Although the SvO2 values demonstrated an increased
trend, the difference failed to reach statistical significance.
Because SvO2 is a global measure and reflects an
amalgam of oxygen consumptions and utilizations from all
of the perfused organs, it may fail to reflect cardiac index
increases in already hyperdynamic patients. Alternatively,
the increased cardiac performance may have increased
perfusion to areas that were not maximally utilizing the
delivered oxygen. The increased extraction ratio of these
segments may have offset the expected increase in SvO2.
An increase in extraction ratio with additional work has
been identified in patients who were ultimately destined to
fail a weaning trial [9]. Because the present study was per-
formed for only a limited period, it is impossible to
comment with any degree of certainty on whether this
mechanism was operative in our patient population.
Nonetheless, there was a small increase in SvO2 in the
patients on APRV, although this was not statistically signifi-
cant. This small increase correlates quite well with an iden-
tifiable and statistically significant increase in urine output.
It is useful to speculate on the potential financial implica-
tions of nearly eliminated neuromuscular blocking agent
use, reduced sedative use, and diminished pressor use.
Such cost savings may translate into real savings for a
hospital. Additionally, nursing time is liberated, and may
potentially be redirected to primary patient care and family
liaison activities. Because a significant proportion of pres-
sors utilized in this select patient population are used to
support oxygen delivery, a PAC is also frequently utilized
to guide such therapy. If the pressors are eliminated, then
the PAC may also be unnecessary. This potential reduc-
tion in PAC utilization is probably real, because many PAC
placement schemes require insertion of PAC for the evalu-
ation of cardiac performance with high PEEP levels or ele-
vated mean airway pressure levels. Each of these
pressures are markers of increased intrathoracic pressure,
increased pressure on the right atrium, and potentially
reduced venous return and, hence, cardiac output. APRV
may make such assessments a less frequent occurrence.
Treating patients with APRV may seem at odds with the
recent US National Institutes of Health ARDSNet study
[1], as well as the closely related study of Amato et al
[10]. Each of these studies holds forth the promise of
increased survival using a combination of lower tidal
volumes, reduced peak airway pressures, permissive
hypercapnia, and the elimination of lower inflection points
on the static pressure–volume curve (as a guide to optimal
PEEP). The common denominator is matching gas delivery
rates, volumes, and durations to an individual patient’s
unique lung dynamics, including the dynamics of their
chest wall and heart size. Each of the factors that are
patient specific impacts on the volume of available and
recruitable lung. The strategies suggested above are
designed to avoid overinflating a given lung, with resultant
volutrauma and biotrauma, while maximizing the recruit-
ment of available alveolar units.
This is the exact premise and promise behind APRV in a
spontaneously breathing patient. The slow gas delivery
rates and long Thigh times are designed to achieve better
matching of regional time constant variations and to
enable more uniform gas delivery to a greater number of
alveolar units than is possible with conventional ventilation
strategies. The patient’s ability to exhale at any time
Available online http://ccforum.com/content/5/4/221
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sensures that, when the patient’s lung volume is ‘full’, excess
volume may be eliminated through an open and floating
expiratory valve. In this way overdistension is avoided. A
related strategy is constant flow ventilation, as championed
by Slutsky and coworkers [11]. However, constant-flow
ventilation is hampered by difficulties related to carbon
dioxide clearance in humans, and the resultant respiratory
acidosis. This problem is eliminated by the release phase
of APRV. Optimal recruitment of alveolar units is achieved
by developing intrinsic PEEP with a short release phase, as
well as through the principle of alveolar interdependency
utilizing the pores of Kohn. Despite seeming disparity,
APRV and the ARDSNet study have virtually identical goals
that are achieved using different strategies.
Conclusion
APRV may be safely instituted in patients with ALI
and/or ARDS. In the present study population, utilizing
the spontaneous breathing that is implicit in APRV sub-
stantially decreased the need for neuromuscular block-
ade and heavy sedation as part of a management
strategy for hypoxemic respiratory failure, as compared
with inverse ratio PCV. The lower peak and mean airway
pressure with APRV lead to decreased transmitted
intrathoracic pressure, and a reduction in the central
venous pressure of patients with ALI and/or ARDS. The
reduced intrathoracic pressure enhances venous return,
and therefore cardiac performance, with a decreased
pressor requirement to support mean arterial pressure
and oxygen delivery. Further study of ARPV is warranted
to discover its impact on resource utilization and
outcome in patients with ALI.
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